2005
|
||
|---|---|---|
|
January
January; 55 (1): 1 - 134 |
February
February; 55 (2): 135 - 281 Supplement: Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic |
March
March; 55 (3): 283 - 399 Supplement: Dalbavancin, a novel second-generation lipoglycopeptide agent for the treatment of serious Gram-positive infections |
|
April
April; 55 (4): 401 - 600 |
May
May; 55 (5): 601 - 814 |
June
June; 55 (6): 815 - 1057 |
|
July
July; 56 (1): 1 - 255 |
August
August; 56 (2): 257 - 445 |
September
Supplement: Itraconazole and the management of systemic fungal infections September; 56 (3): 447 - 606 |
|
October
Supplement: The Alexander Project: the benefits from a decade of surveillance October; 56 (4): 607 - 797 |
November
November; 56 (5): 799 - 990 |
December
December; 56 (6): 991 - 1188 |